B7

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
Telephone, ASCO, CEO, GLOBE, Neoplasm, Cancer, Patient, Enoblituzumab, Food, Prostate cancer, Investor relations, American Society of Clinical Oncology, Annual general meeting, Half-life, Conference call, GMP, Safety, B7, BLA, Webcast, Conference, ID, PSA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ADC, Teplizumab, PD-1, European Medicines Agency, CD123, AML, Johns Hopkins University, Large-cell lung carcinoma, MCRPC, D, SCCHN, Â, B7-H3, Head, Melanoma, FDA, Acute myeloid leukemia, PDUFA, Mab, Microdeletion syndrome, Macrogen, Society, Workforce, Cytokine release syndrome, Review, Neck, Company, Therapy, Prescription Drug User Fee Act, NASDAQ, Research, Anti-CD3 monoclonal antibody, Pharmaceutical industry, Fine chemical, Vaccine, Incyte

ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.

Key Points: 
  • ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.
  • We made important progress in the second quarter, during which we completed enrollment in a Phase 1/2 dose expansion study of lorigerlimab, a PD-1 CTLA-4 DART molecule.
  • Recent progress and anticipated events in 2022 related to MacroGenics investigational product candidates in clinical development are highlighted below.
  • Revenue for the quarter ended June30, 2022 included MARGENZA net sales of $4.7 million, compared to $3.2million for the quarter ended June30, 2021.

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 3, 2022
D, MCRPC, Enoblituzumab, American Association for Cancer Research, MSS, Safety, Cytokine release syndrome, Half-life, Conference call, PD-1, B7-H3, CEO, TNBC, Melanoma, NASDAQ, Macrogen, Company, Pembrolizumab, Immunotherapy, Patient, Clinical trial, Program, FDA, American Association, Teplizumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biologics license application, Prostate, ORR, PARP, Large-cell lung carcinoma, B7, IND, Conjugation, Research, BLA, CD123, Association, Acute myeloid leukemia, NSCLC, DART, Prostate cancer, AACR, CRC, RPF, Head, ADC, AML, SCCHN, T1D, GLOBE, Food, Webcast, Therapy, Investor relations, Journal, Lymphatic system, PD-L1, PDUFA, Fine chemical, Pharmaceutical industry, Vaccine, Medical imaging, Palladium, Video game, Cancer, Incyte, Conference

ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March31, 2022.

Key Points: 
  • ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March31, 2022.
  • Following a constructive FDA meeting in March 2022, MacroGenics finalized the Phase 2/3 study design of MGC018 in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • R&D Expenses: Research and development expenses were $61.4 million for the quarter ended March31, 2022, compared to $53.1 million for the quarter ended March31, 2021.
  • MacroGenics will host a conference call today at 4:30 p.m. (ET) to discuss financial results for the quarter ended March31, 2022, and provide a corporate update.

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Conclusion, 2D, Squamous cell carcinoma, Head, Trike, CD28, Mouth, HNSCC, Goal, Prostate cancer, GLOBE, FANCA, University, Security (finance), ADCC, Toxicity, Cancer, Radiation, Therapy, NASDAQ, CD16, Immunotherapy, Annual report, Man, Ovarian cancer, Brain, FA, Society, Muscle, Melanoma, CRISPER, Fanconi anemia, NK, Patient, Company, B7, Form 10-K, HPV, Exocrine gland, Tumor microenvironment, Woman, Neoplasm, Incidence, KO, Throat, GT, Flow cytometry, University of Minnesota, Vaccine, Medical imaging, Neck

BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that it is presenting pre-clinical data at the American Association For Cancer Research Annual Meeting 2022. The poster presentation titled, “#3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas,” presented by Dr. Jeff Miller's laboratory, University of Minnesota.

Key Points: 
  • The poster presentation titled, #3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas, presented by Dr. Jeff Miller's laboratory, University of Minnesota.
  • Background - According to the American Society of Clinical Oncologys information hub, head and neck cancers account for about 4% of all cancers in the United States.
  • In 2021, an estimated 66,630 people (48,740 men and 17,890 women) will develop head and neck cancer.
  • For more information about squamous cell carcinomas of the head and neck please click here .

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Safety, GMP, Twitter, Form 20-F, Annual report, Private Securities Litigation Reform Act, Risk, Company, CLDN6, Antibody, Immune system, U.S. Securities and Exchange Commission, Cancer, Lishui, NDA, Degenerative disease, Intellectual property, CD45, CD8, Toxicity, Patient, WeChat, Enoblituzumab, Neoplasm, Technology, COVID-19, B7, Liver, B7-H3, FC, LinkedIn, Vaccine, Pharmaceutical industry

Taken together, these data support further development of TJ-C64B towards clinical development subsequently.

Key Points: 
  • Taken together, these data support further development of TJ-C64B towards clinical development subsequently.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins.
  • B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer.
  • TJ-C64B is a bispecific antibody simultaneously targeting tumor associated antigen Claudin 6 (CLDN6) and costimulatory molecule 4-1BB for CLDN6+ tumor treatment.

GIMME Beauty Launches GIMME Drops, Gummies Formulated to Promote Hair Health

Retrieved on: 
Wednesday, March 9, 2022
People, Beauty, American Academy, AAD, Mineral, SALT, Uncombable hair syndrome, Biotin, Biotinidase, Vitamin, Organic acid, Instagram, Argania, Give Me Beauty... Or Give Me Death!, Health, Sensation, Milk, Hair loss, GLOBE, Cooking, Patient, Nut, GIM, Allergen, Fruit, Hair, Vitamin E, COVID-19, B7, Coconut oil, Linoleic acid, Cosmetics, Dietary supplement, Facebook

SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- GIMME Beauty , the viral social media sensation delivering innovative hair care solutions for the beauty industry announces GIMME Drops , gummies developed to provide a unique blend of vitamins and minerals to support hair health and vitality.

Key Points: 
  • SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- GIMME Beauty , the viral social media sensation delivering innovative hair care solutions for the beauty industry announces GIMME Drops , gummies developed to provide a unique blend of vitamins and minerals to support hair health and vitality.
  • Featuring biotin, argan oil and several essential vitamins, GIMME Drops may support the body's natural processes for maintaining healthy hair.
  • Biotin, also known as vitamin B7, is an over-the-counter supplement that has been widely used to promote healthy hair.
  • GIMME Beauty's vision is to design innovative hair solutions that disrupt the status quo of the health and beauty hair care category.

Herbalife Nutrition Now Offers Herbalife24® Liftoff® Stick Packs for Portability, Easy Prep and Consumption

Retrieved on: 
Monday, August 23, 2021
Sports, General Sports, Health, General Health, Women, Food, Beverage, Men, Soccer, Retail, Fitness & Nutrition, Consumer, Fatigue, Company, Inositol, Stick, B7, HLF, Vitamin C, Ginsenoside, Liftoff, LA, NSF International, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Metabolism, LA Galaxy, Herbalife Nutrition, NYSE, Hunger, Education, Athlete, Soft drink, Sport, Dietary supplement

Herbalife Nutrition today announced the newest addition to its Herbalife24 product line, Liftoff.

Key Points: 
  • Herbalife Nutrition today announced the newest addition to its Herbalife24 product line, Liftoff.
  • Specifically, as the exclusive sports nutrition partner of the LA Galaxy, Herbalife Nutrition received feedback that its popular Liftoff product was a favorite among players.
  • The product is available exclusively through Herbalife Nutrition independent distributors who support their customers who are everyday athletes, reinforcing our purpose for the Herbalife24 line: nutrition for the 24-hour athlete.
  • Through the Company's global campaign to eradicate hunger, Herbalife Nutrition is also committed to bringing nutrition and education to communities around the world.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

Retrieved on: 
Friday, July 30, 2021
XMT, VTCN1, ADC Airlines, B7

ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.
  • To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 3876353.
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
  • The Companys early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Companys Immunosynthen platform.

Biotin Water® Hair, Skin, & Nails Makes Its Way To Publix Supermarkets

Retrieved on: 
Friday, June 11, 2021
Organic compounds, Chemical compounds, Biotin, Cofactors, Ureas, Chemistry, Nail, B7

ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.

Key Points: 
  • ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.
  • 2T Water, LLC owns the exclusive rights to distribute Biotin Water Hair, Skin, and Nails which is the first biotin infused beverage that delivers 300 mcg per 16oz with zinc and folic acid included in the proprietary formula.
  • Biotin Water Hair, Skin, and Nails is formulated to ensure the body is properly hydrated while enjoying the many benefits of B7, often considered the most overlooked vitamin.
  • This new introduction of Biotin Water gives consumers more locations throughout the southeast to purchase Biotin Water in a great grocery chain.

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

Retrieved on: 
Wednesday, May 19, 2021
Instant messaging clients, Software, Clusters of differentiation, Immune system, CD276, Immune checkpoint, B7, Adium

B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • Under the terms of the agreement, Adium will employ its sales and marketing expertise to distribute DANYELZA and omburtamab, if approved, in the territory.
  • In addition, Adium will submit registration files on behalf of the Company in certain parts of the territory.
  • Adium distributes its products in 18 Latin American & Caribbean countries including Brazil, Mexico and Colombia.

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting

Retrieved on: 
Saturday, April 10, 2021
Gynaecological cancer, Breast cancer, Ovarian cancer, B7, XMT, Medical specialties, Health, Clinical medicine

We expect to complete IND-enabling studies and advance both XMT-1660 and XMT-2056 into the clinic in early 2022.

Key Points: 
  • We expect to complete IND-enabling studies and advance both XMT-1660 and XMT-2056 into the clinic in early 2022.
  • Details of the posters are as follows:
    These data show that B7-H4 is a promising target for a Dolasynthen ADC due to its expression and function.
  • B7-H4 is expressed across multiple different tumor types with high unmet medical need, including breast, endometrial and ovarian.
  • In the MX-1 triple-negative breast model, XMT-1660 showed complete, durable regressions of tumors at a DolaLock payload dose of 0.15 mg/kg.